FDA Pushes Merck's Pneumococcal Vaccine Decision Date Into July For Expanded Use In Kids

Comments
Loading...

The FDA has extended the Prescription Drug User Fee Act (PDUFA) date of the supplemental marketing application for Merck & Co Inc's  MRK pneumococcal 15-valent conjugate vaccine in infants and children to July 1, 2022.

Overview Rating:
Good
62.5%
Technicals Analysis
66
0100
Financials Analysis
60
0100
Overview
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!